Risk Modeling Articles & Analysis: Older
5 news found
The first candidate under development by Oncovita, MVdeltaC, is an immunotherapeutic treatment for solid tumors and has demonstrated remarkable immunogenic oncolysis properties in human or syngeneic tumor models, e.g. mesothelioma, bladder, neuroblastoma, etc. The production method in accordance with good manufacturing practice (GMP) is under development in order to initiate ...
ByOncoVITA
In 2016, APA ACO applied for and was approved by CMS to participate in the Next Generation Accountable Care Organization (ACO) Model. APA ACO was approved to participate in the All-Inclusive Population-Based Payment ("AIPBP") track, which was the most advanced risk-taking payment model. ...
“We are creating an opportunity to fully outsource small molecule discovery while providing a true risk-sharing model with advanceable leads and candidates with the goal of helping companies scale faster, translating more biological insight into candidates to make better drugs for patients, ...
Orma Health's real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring ("RPM"), mental health support, chronic disease management, and more. ...
Key speakers confirmed:• Dr Jean MacDonald, General Counsel, EDF• David Boone, UK Nuclear Director, Fluor• Martin Grant, Nuclear Manager, Atkins Global • Norman Harrison, CEO, UK IAEA• Roger Clayson, Interim Head of Legal, Nuclear Decommissioning Authority • Adrian Worker, Programme Director – UK Nuclear New Build, Amec• Johan Rautenbach, Director – Office of Legal Affairs, IAEAKey topics to be ...